Abstract:Over the last decade, based on the extensive development of preclinical animal studies and clinical trials, the efficacy, and mechanisms of immunotherapy have been fully explored. Significant and lasting clinical responses with immunotherapy provide a new breakthrough treatment for a variety of refractory cancer histologies, which gradually change the treatment pattern of tumors. However, although immune checkpoint inhibitor drugs are promising for achieving longer-term efficacy, their benefits in the overall population are still very low, such as low frequency of response in some common tumor types such as breast and prostate, and heterogeneity in the degree of response among different tumor lesions in the same patient, making immunotherapy with many limitations and challenges. Most patients do not respond to immunotherapy or inevitably develop resistance to treatment after a period of treatment, manifesting with primary resistance or acquired resistance who initially respond to treatment. The mechanisms of tumor immune resistance are very complex and involve multiple aspects such as genes, metabolism, inflammation, and abnormal neovascularization. Currently, many mechanisms of immunotherapy resistance have been characterized, and more continue to be uncovered. These efforts can improve the quality of medical care for cancer diagnosis and treatment, which improve the quality of life of patients, and finally lead to accurate individualized treatment. This review discusses mechanisms of cancer immunotherapy resistance including tumor-intrinsic factors and tumor-extrinsic factors.

Mechanisms of Tumor Resistance to Immune Checkpoint Blockade and Combination Strategies to Overcome Resistance

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance

Tumor Immune Checkpoints and Their Associated Inhibitors

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?

Lessons Learned from the Blockade of Immune Checkpoints in Cancer Immunotherapy

Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance

Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms

Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Metabolic Interventions Combined with CTLA-4 and PD-1/PD-L1 Blockade for the Treatment of Tumors: Mechanisms and Strategies.

Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer

Mechanisms of Cancer Resistance to Immunotherapy

Progress of Drug Resistance Mechanism in Checkpoint Inhibitors

Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies

Resistance to immune checkpoint inhibitors and the tumor microenvironment

Immune Checkpoint Inhibitor-Based Strategies For Synergistic Cancer Therapy

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired